- Home
- ALKS vs OWLS Comparison
ALKS vs OWLS Comparison
Compare ALKS & OWLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALKS
- OWLS
- Stock Information
- Founded
- ALKS 1987
- OWLS 2010
- Country
- ALKS Ireland
- OWLS Taiwan
- Employees
- ALKS N/A
- OWLS N/A
- Industry
- ALKS Biotechnology: Pharmaceutical Preparations
- OWLS Computer Software: Prepackaged Software
- Sector
- ALKS Health Care
- OWLS Technology
- Exchange
- ALKS Nasdaq
- OWLS Nasdaq
- Market Cap
- ALKS 5.0B
- OWLS 4.9B
- IPO Year
- ALKS 1991
- OWLS N/A
- Fundamental
- Price
- ALKS $29.21
- OWLS $11.40
- Analyst Decision
- ALKS Strong Buy
- OWLS
- Analyst Count
- ALKS 13
- OWLS 0
- Target Price
- ALKS $42.54
- OWLS N/A
- AVG Volume (30 Days)
- ALKS 2.1M
- OWLS 571.9K
- Earning Date
- ALKS 10-28-2025
- OWLS 01-01-0001
- Dividend Yield
- ALKS N/A
- OWLS N/A
- EPS Growth
- ALKS 21.99
- OWLS N/A
- EPS
- ALKS 2.08
- OWLS N/A
- Revenue
- ALKS $1,505,296,000.00
- OWLS $7,569,630.00
- Revenue This Year
- ALKS N/A
- OWLS N/A
- Revenue Next Year
- ALKS $1.59
- OWLS N/A
- P/E Ratio
- ALKS $14.32
- OWLS N/A
- Revenue Growth
- ALKS N/A
- OWLS 18.29
- 52 Week Low
- ALKS $25.17
- OWLS $7.48
- 52 Week High
- ALKS $36.45
- OWLS $90.00
- Technical
- Relative Strength Index (RSI)
- ALKS 42.95
- OWLS N/A
- Support Level
- ALKS $29.94
- OWLS N/A
- Resistance Level
- ALKS $32.02
- OWLS N/A
- Average True Range (ATR)
- ALKS 1.13
- OWLS 0.00
- MACD
- ALKS -0.32
- OWLS 0.00
- Stochastic Oscillator
- ALKS 9.12
- OWLS 0.00
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.